Modeling of farnesyltransferase inhibition by some thiol and non-thiol peptidomimetic inhibitors using genetic neural networks and RDF approaches.
暂无分享,去创建一个
Maykel Pérez González | Julio Caballero | Aliuska Morales Helguera | Michael Fernández | Alain Tundidor-Camba | M. Fernández | Julio Caballero | M. P. González | A. M. Helguera | A. Tundidor‐Camba
[1] Bahram Hemmateenejad,et al. Genetic Algorithm Applied to the Selection of Factors in Principal Component-Artificial Neural Networks: Application to QSAR Study of Calcium Channel Antagonist Activity of 1, 4-Dihydropyridines (Nifedipine Analogous) , 2003, J. Chem. Inf. Comput. Sci..
[2] G. Prendergast,et al. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. , 2000, Current opinion in cell biology.
[3] J. Gasteiger,et al. Finding the 3D structure of a molecule in its IR spectrum , 1997 .
[4] Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase. , 1999, Bioorganic & medicinal chemistry letters.
[5] Douglas M. Hawkins,et al. The Problem of Overfitting , 2004, J. Chem. Inf. Model..
[6] Bahram Hemmateenejad,et al. Toward an Optimal Procedure for PC-ANN Model Building: Prediction of the Carcinogenic Activity of a Large Set of Drugs , 2005, J. Chem. Inf. Model..
[7] David A Winkler,et al. Neural networks as robust tools in drug lead discovery and development , 2004, Molecular biotechnology.
[8] F. Burden,et al. Robust QSAR models using Bayesian regularized neural networks. , 1999, Journal of medicinal chemistry.
[9] M. Schlitzer,et al. Non-thiol farnesyltransferase inhibitors: utilization of an aryl binding site by 5-arylacryloylaminobenzophenones. , 2002, Bioorganic & medicinal chemistry.
[10] Frank R Burden,et al. Broad-based quantitative structure-activity relationship modeling of potency and selectivity of farnesyltransferase inhibitors using a Bayesian regularized neural network. , 2004, Journal of medicinal chemistry.
[11] M Karplus,et al. Evolutionary optimization in quantitative structure-activity relationship: an application of genetic neural networks. , 1996, Journal of medicinal chemistry.
[12] M. Karplus,et al. Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors. , 1996, Journal of medicinal chemistry.
[13] T. Kohonen. Self-organized formation of topographically correct feature maps , 1982 .
[14] F. Burden,et al. A quantitative structure--activity relationships model for the acute toxicity of substituted benzenes to Tetrahymena pyriformis using Bayesian-regularized neural networks. , 2000, Chemical research in toxicology.
[15] Johann Gasteiger,et al. Deriving the 3D structure of organic molecules from their infrared spectra , 1999 .
[16] S. Ng,et al. Potent and orally bioavailable noncysteine-containing inhibitors of protein farnesyltransferase. , 1999, Bioorganic & medicinal chemistry letters.
[17] Maykel Pérez González,et al. TOPS-MODE versus DRAGON descriptors to predict permeability coefficients through low-density polyethylene , 2003, J. Comput. Aided Mol. Des..
[18] M. Schlitzer,et al. Non-thiol farnesyltransferase inhibitors: N-(4-Acylamino-3-benzoylphenyl)-4-nitrocinnamic acid amides. , 2002, Bioorganic & medicinal chemistry.
[19] Bobby G. Sumpter,et al. Theory and Applications of Neural Computing in Chemical Science , 1994 .
[20] R. Lipnick. Outliers: their origin and use in the classification of molecular mechanisms of toxicity. , 1991, The Science of the total environment.
[21] D. Pompliano,et al. Potent, non-thiol inhibitors of farnesyltransferase. , 1998, Bioorganic & medicinal chemistry letters.
[22] D. Pompliano,et al. Intramolecular fluorescence enhancement: a continuous assay of Ras farnesyl:protein transferase , 1992 .
[23] Zhanghua Wu,et al. Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. , 1998, Biochemistry.
[24] Johann Gasteiger,et al. Chemical Information in 3D Space , 1996, J. Chem. Inf. Comput. Sci..
[25] Teuvo Kohonen,et al. Self-organized formation of topologically correct feature maps , 2004, Biological Cybernetics.
[26] P. Casey,et al. Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.
[27] C. Luttmann,et al. Multivariate data analysis using D-optimal designs, partial least squares, and response surface modeling: A directional approach for the analysis of farnesyltransferase inhibitors. , 2000, Journal of medicinal chemistry.
[28] Maykel Pérez González,et al. A TOPS-MODE approach to predict adenosine kinase inhibition. , 2004, Bioorganic & medicinal chemistry letters.
[29] Yuji Takahata,et al. Comparison between Neural Networks (NN) and Principal Component Analysis (PCA): Structure Activity Relationships of 1, 4-Dihydropyridine Calcium Channel Antagonists (Nifedipine Analogues) , 2003, J. Chem. Inf. Comput. Sci..
[30] J. Zupan,et al. Neural Networks in Chemistry , 1993 .
[31] H. Díaz,et al. A TOPS-MODE approach to predict permeability coefficients , 2004 .
[32] M. Schlitzer,et al. Synthesis, molecular modeling, and structure-activity relationship of benzophenone-based CAAX-peptidomimetic farnesyltransferase inhibitors. , 2001, Journal of medicinal chemistry.
[33] J. Devillers,et al. Practical applications of quantitative structure-activity relationships (QSAR) in environmental chemistry and toxicology , 1990 .
[34] Julio Caballero,et al. Linear and nonlinear modeling of antifungal activity of some heterocyclic ring derivatives using multiple linear regression and Bayesian-regularized neural networks , 2006, Journal of molecular modeling.
[35] B. Seizinger,et al. Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. , 1996, Journal of medicinal chemistry.
[36] G. Prendergast,et al. Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB , 1999, Molecular and Cellular Biology.
[37] S. Sebti,et al. New approaches to anticancer drug design based on the inhibition of farnesyltransferase , 1998 .
[38] G. Klebe,et al. Non-thiol farnesyltransferase inhibitors: N-(4-acylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. , 2003, Bioorganic & medicinal chemistry.
[39] Ernesto Estrada,et al. A novel approach for the virtual screening and rational design of anticancer compounds. , 2000, Journal of medicinal chemistry.
[40] Maykel Pérez González,et al. Quantitative structure-activity relationship to predict differential inhibition of aldose reductase by flavonoid compounds. , 2005, Bioorganic & medicinal chemistry.
[41] Johann Gasteiger,et al. Neural networks in chemistry and drug design , 1999 .
[42] David J. C. MacKay,et al. Bayesian Interpolation , 1992, Neural Computation.
[43] S. Ng,et al. Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy. , 1999, Journal of medicinal chemistry.